Healthcare ❯ Pharmaceuticals ❯ Drug Approval

FDA

Clinical Trials Novo Nordisk Bristol Myers Squibb Eli Lilly Lenacapavir Regulatory Affairs Vaccine Oversight Global Health Foundayo Esketamine Compounded Drugs Familial Chylomicronemia Syndrome Nereus SPRAVATO Neffy Wegovy KYGEVVI Fast-Track Review Imaavy Biologics License Application Monoclonal Antibodies Weight Loss Medications Johnson & Johnson Ionis Pharmaceuticals Zepbound New Drug Mechanisms Disease-Modifying Therapies

FDA Approves Zanvastro as First Treatment for Alexander Disease

Validation of Ionis’s antisense approach shifts attention to U.S. launch execution, real-world durability, pricing, and patient access

FDA Expands Tzield Use to Delay Type 1 Diabetes in Children Ages 1 to 7

Hims & Hers Soars as Novo Nordisk Reinstates Supply Deal for Ozempic and Wegovy

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

FDA Issues Second Rejection of Atara’s EBV+ PTLD Therapy Tabelecleucel

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

Arrowhead Gains FDA Approval for Redemplo as Results Surge and Shares Hit Three-Year High

WHO Endorses Twice-Yearly Lenacapavir Injections for HIV Prevention

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention